MONTREAL, April 19, 2018 /CNW/ -- Paladin Labs Inc., a
subsidiary of Endo International plc (NASDAQ: ENDP), announced
today the launch of Unisom® Snore Relief, a new
snore relief product from the makers of Unisom®, the
trusted and established sleeping aid brand in Canada.
New Unisom® Snore Relief is an OTC
(over-the-counter) branded throat spray available in Canada which is indicated to help relieve
symptoms associated with snoring.
Snoring is a common condition that affects 2/3 of Canadian
adults1. It occurs when the air flowing through the
passages at the back of the mouth and nose is constricted. This
happens during sleep because the throat muscles, soft palate and
uvula are relaxed. The narrower the airway, the faster the air
flows, and the more these tissues vibrate. It's these vibrations
along the airway that cause the snoring noise2.
"We are pleased to announce the launch of Unisom®
Snore Relief in Canada," said Livio Di Francesco, VP
& General Manager of Paladin Labs Inc. "This new throat spray
can help Canadians relieve their symptoms of snoring in an easy to
use format. Unisom® Snore Relief expands our
Unisom® product line."
Paladin obtained the exclusive rights to market and
sell Unisom® Snore Relief in Canada from
PuraNox Trading BV, Oosterhout, Netherlands in May 2017.
About Unisom® Snore
Relief
Unisom® Snore Relief is a natural health
product (NHP) specifically indicated to help relieve symptoms
associated with snoring. This product may not be right for all
patients. Always read and follow the label.
About Unisom®
Unisom® is
an effective and trusted sleep aid for occasional insomnia; it
helps to reduce difficulty falling asleep. The brand has been on
the Canadian market for over 35 years. The makers of Unisom® offer
products including Unisom Extra-Strength Tablets and Soft Gel
Capsules.
For more information, please visit www.unisom.ca.
Unisom® Snore Relief suggested retail
price: $24.99 – $29.99 (45
mL Aerosol).
Available on pharmacy shelves.
About Paladin Labs Inc.
Paladin Labs Inc.,
headquartered in Montreal, Canada, is a specialty pharmaceutical company
focused on acquiring or in-licensing innovative pharmaceutical
products for the Canadian market. Paladin has a focused marketing
and sales organization that has helped it evolve into one
of Canada's leading specialty pharmaceutical companies.
Paladin is an operating company of Endo International plc
(NASDAQ: ENDP), a highly focused generics and specialty
branded pharmaceutical company delivering quality medicines to
patients in need through excellence in development, manufacturing
and commercialization. Learn more at www.endo.com or
www.paladin-labs.com.
Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and Canadian securities legislation. Statements including words
such as "believes," "expects," "anticipates," "intends,"
"estimates," "plan," "will," "may," "look forward," "intend,"
"guidance," "future" or similar expressions are forward-looking
statements. Because these statements
reflect Endo's current views, expectations and beliefs
concerning future events, these forward-looking statements involve
risks and uncertainties. Although Endo believes that
these forward- looking statements and information are based upon
reasonable assumptions and expectations, readers should not place
undue reliance on them, or any other forward- looking statements or
information in this news release. Investors should note that many
factors, as more fully described in the documents filed
by Endo with securities regulators in the United
States and Canada including under the caption "Risk
Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K
filings with the Securities and Exchange Commission and
with securities regulators in Canada on System for
Electronic Document Analysis and Retrieval ("SEDAR") and as
otherwise enumerated herein or therein, could
affect Endo's future financial results and could
cause Endo's actual results to differ materially from
those expressed in forward-looking statements contained
in Endo's Annual Report on Form 10-K. The forward-looking
statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate,
could cause Endo's actual results to differ materially
from expected and historical results. Endo assumes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise, except as may be required under applicable securities
law.
References
1Canadian Society of
Otolaryngology-Head & Neck Surgery – Snoring
2 Scharf MB. Sleep Disorders Vol 1. 3rd ed. (1991)
SOURCE Endo International plc